The information in the press release is intended for investors.
Third quarter, July - September 2023
- Net revenue amounted to TSEK 0 (2,907) and other revenue to TSEK 0 (0)
- The result for the period amounted to TSEK -6,260 (-32,513)
-
Earnings per share amounted to
SEK -0.04 (-0.20) -
Cash and cash equivalents as of
September 30 amounted to TSEK 144,226 (234,983)
January - September 2023
- Net revenue amounted to TSEK 721 (10,940) and other revenue to TSEK 23 (1)
- The result for the period amounted to TSEK -28,162 (-134,420)
-
Earnings per share amounted to
SEK -0.17 (-0.38)
Significant events during the third quarter 2023
- On
July 4 , presented the conclusions from the in-depth analysis of data from the Phase III study AGENT. The results from the analysis support the hypothesis that a different dose and administration regimen has the potential to improve the efficacy of the company's drug candidate arfolitixorin.
Significant events after the event of the period
- On
October 5 , the company announced that the company has taken notice of the results from the investigator-initiated study Modelle 001. Isofol will quality review the material when a study report is available. -
On
November 9 , the company obtained a request to call an extraordinary general meeting from shareholders representing a minority of at least 10 percent in order to take a decision on the election of additional board members. The notice to the extraordinary general meeting will be announced as soon as is practically possible.
CEO´s comment:
"In addition to our ongoing collaboration with a Norwegian laboratory, we recently engaged a US-based company in order to generate more data to gain a strong basis for decisions on a potential minor clinical study in a time-efficient way. During the fourth quarter, we have planned a first meeting with the
For more information, please contact
E-mail: roger.tell@isofolmedical.com
Phone: +46 (0) 760 29 39 11
Roy Jonebrant, Acting Chief Financial Officer
E-mail: roy.jonebrant@isofolmedical.com
Phone: +46 (0) 708 48 12 36
The information was submitted for publication, through the agency of the contact person set out above, at
About Isofol Medical AB (publ)
www.isofolmedical.com
https://news.cision.com/isofol-medical-ab--publ-/r/isofol-medical-ab--publ--publishes-interim-report--january-september-2023,c3873025
https://mb.cision.com/Main/15598/3873025/2421445.pdf
https://mb.cision.com/Public/15598/3873025/8c3d127ca3874cfb.pdf
(c) 2023 Cision. All rights reserved., source